Renal tumours: Locally advanced and metastatic disease
Poster Session 22

Saturday 10 July
17:00 - 18:00

Location
Virtual Room 8

Chairs
To be confirmed
M. Oya, Tokyo (JP)

We encourage you to view the abstracts prior to the session:

• On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
• On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

Learning objectives
Learning cutting edges of the subjects below:

• Surgeries for RCC with IVC thrombus
• Variant histology of RCC and angiomyolipoma including sarcomatoid variant and epithelioid angiomyolipoma
• Genetic testing of RCC and TSC
• Managing adverse events for patients treated with targeted agents or immune-checkpoint inhibitors
• Novel biomarkers for metastatic RCC
• Role of cytoreductive nephrectomy in the era of targeted agents and immunotherapy.

17:00 - 17:01
Introduction

17:01 - 17:15
Surgical aspects of advanced kidney tumors

P0623
Renal functional outcomes at 5 years from radical and partial nephrectomies in normal renal function patients: An untold story of hyperfiltrations
F. Trevisani, Milan (IT)

P0624
Prostate Specific Membrane Antigen (PSMA) PET/CT compared to standard of care imaging in the assessment of renal cancers: A multi-institutional series
A. Tariq, Windsor (AU)

P0625
Robot-assisted radical nephrectomy and inferior vena cava level I-III thrombectomy: An update on perioperative and mid-term oncologic outcomes from a tertiary-referral centre
U. Anceschi, Rome (IT)

P0626
Survival analysis of Renal Cell Carcinoma with venous tumor thrombus: A single centre 20-yr experience
M.L. Righetto, Padova (IT)

P0627
Predictive factors of recurrence after surgery in patients with non-metastatic renal cell carcinoma with venous tumor thrombus (urocrr-56 study) and the impact of adjuvant treatment
M. Baboudjian, Marseille (FR)

P0628
Radical nephrectomy and caval thrombectomy with heart beating technique for renal cell cancer with tumor thrombus extension into inferior vena cava and right atrium: A less invasive multidisciplinary approach
S. Guzzo, Vanzago (IT)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>P0629</th>
<th>P0630</th>
<th>P0631</th>
<th>P0632</th>
<th>P0633</th>
<th>P0634</th>
<th>P0635</th>
<th>P0636</th>
<th>P0637</th>
<th>P0638</th>
<th>P0639</th>
<th>P0640</th>
<th>P0641</th>
<th>P0642</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:07 - 17:15</td>
<td>Discussion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:23 - 17:31</td>
<td>Discussion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:55 - 17:55</td>
<td>Discussion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
P0643  Is presence of vena caval thrombosis in primary tumor associated with worsened outcomes in metastatic renal cell carcinoma: Analysis of the REMARCC registry  
M.F. Meagher, La Jolla (US)

P0644  Optimizing patient selection for deferred cytoreductive nephrectomy in the contemporary era of targeted therapy  
J. Choy, London (GB)

P0645  The role of cytoreductive nephrectomy for metastatic renal cell carcinoma in National Health Insurance Service  
J. Gook, Seoul (KR)

P0646  Cytoreductive nephrectomy in patients receiving TKI therapy versus immune checkpoint inhibitor therapy: Comparative outcome analysis of the REMARCC registry  
M.F. Meagher, La Jolla (US)

P0647  Nephrectomy after complete response to immune checkpoint inhibitors for Metastatic Renal Cell Carcinoma (mRCC): A surgical challenge allowing favorable oncological outcomes  
G. Pignot, Marseille (FR)

P0648  Predictors of complications after cytoreductive nephrectomy in the immunotherapy era: Results from a multicenter international study  
M. Marchioni, Cantalice (RI) (IT)

P0649  Surgical safety of Cytoreductive Nephrectomy (CN) following pretreatment with Immune Checkpoint Inhibition (ICI) combination therapy in primary metastatic clear-cell Renal Carcinoma (mccRCC)  
N.M. Graafland, Amsterdam (NL)

P0650  Prognostic effect of preoperative serum albumin to globulin ratio in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma  
E. Laukhtina, Moscow (RU)

P0651  Management of local recurrence after radical nephrectomy: Surgical removal is still the gold standard. Results from a multicenter international cohort  
M. Marchioni, Cantalice (RI) (IT)

P0652  Urine free glycosaminoglycans as monitoring biomarkers in confined renal cell carcinoma - A prospective observational study  
F. Gatto, Solna (SE)

17:47 - 17:55  Discussion

17:55 - 18:00  Expert summary  
U. Capitanio, Milan (IT)